Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleNasdaq· April 9, 2026

Bitcoin's Scariest Risk Just Became More Likely to Happen. Should You Sell It?

View original at nasdaq.com
Bitcoin's Scariest Risk Just Became More Likely to Happen. Should You Sell It? Key Points Bitcoin is secured by encryption. That encryption is thought to be very burdensome to break with normal computers…
Opening lines of the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Protocol upgrades will almost certainly arrive before any quantum machine can exploit the vulnerability for long-term investors

    60% confidence
  • A full migration to quantum-resistant cryptography for Bitcoin could take about seven years

    60% confidence
  • The encryption-breaking risk posed by quantum computers wouldn't pose an actual threat for approximately 10 years (prior to Google's new research)

    60% confidence
  • If you need the money within five years, this new paper is a reason to temper your Bitcoin allocation

    60% confidence
  • Stock Advisor's total average return is 946% compared to 190% for the S&P 500

    60% confidence
  • Bitcoin was not identified as one of the 10 best stocks for investors to buy now

    60% confidence
  • The quantum threat window just shrank from a comfortable decade to perhaps five to seven years

    60% confidence
  • Bitcoin's encryption can be cracked within minutes by an optimized quantum computer that needs 20X fewer physical qubits than prior estimates

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com